drugset / Trial / NCT00943072

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

NCT00943072

Phase 3 Completed 189 enrolled Regeneron Pharmaceuticals Bayer · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase 3 study to determine the efficacy of VEGF Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion.

Timeline

Start
2009-07
Primary completion
2010-10
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal